MLTX · Company research
MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says (MLTX:NASDAQ) - Seeking Alpha | MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says (MLTX:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 18, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits | MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Stocktwits | MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Moonlake Immunotherapeutics Stock Price Forecast. Should You Buy MLTX? - StockInvest.us | Moonlake Immunotherapeutics Stock Price Forecast. Should You Buy MLTX? StockInvest.us | View source ↗ | StockInvest.us | Oct 9, 2026 | neutral | 0 | 0.6 |
| MoonLake Immunotherapeutics (MLTX) Institutional Ownership 2026 - MarketBeat | MoonLake Immunotherapeutics (MLTX) Institutional Ownership 2026 MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits | MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts Stocktwits | View source ↗ | Stocktwits | Oct 6, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits | MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week Stocktwits | View source ↗ | Stocktwits | Oct 4, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits | MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event Stocktwits | View source ↗ | Stocktwits | Oct 4, 2026 | neutral | 0 | 0.6 |
| MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near - Yahoo Finance | MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near Yahoo Finance | View source ↗ | Yahoo Finance | Sep 11, 2026 | neutral | 0 | 0.6 |
| MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near - Stocktwits | MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near Stocktwits | View source ↗ | Stocktwits | Sep 11, 2026 | neutral | 0 | 0.6 |
| Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake - Stock Titan | Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake Stock Titan | View source ↗ | Stock Titan | Aug 14, 2026 | neutral | 0 | 0.6 |
| MoonLake reports positive Phase 3 PsA data and $537 million cash | MLTX Stock News - Quiver Quantitative | MoonLake reports positive Phase 3 PsA data and $537 million cash | MLTX Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 10, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data - Yahoo Finance | MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data Yahoo Finance | View source ↗ | Yahoo Finance | Aug 3, 2026 | neutral | 0 | 0.6 |
| Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? - Yahoo Finance | Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 31, 2026 | neutral | 0 | 0.6 |
| MLTX Forecast — Price Target — Prediction for 2027 - TradingView | MLTX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? - Yahoo Finance | MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 22, 2026 | neutral | 0 | 0.6 |
| MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing - Yahoo Finance | MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing Yahoo Finance | View source ↗ | Yahoo Finance | May 11, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.